Dyne Therapeutics will present new positive results from the DELIVER trial of z-rostudirsen in DMD, along with details on the Phase 3 trial design for z-basivarsen in DM1. The company will showcase the strength of its pipeline across three neuromuscular diseases at the 2026 MDA Clinical & Scientific Conference. Results from the DELIVER trial showed promising improvements in cardiopulmonary function, while the Phase 3 trial for z-basivarsen in DM1 aims to be field-defining. Dyne’s presentations will highlight the potential of their FORCE™ platform to deliver functional improvement for patients with neuromuscular diseases.

Read more at GlobeNewswire: Dyne Therapeutics Announces Upcoming Presentations Across